S7 Nitric Oxide Booster
S7® is a plant-based, proprietary formula from FutureCeuticals that delivers seven phytonutrient rich botanicals — green coffee bean extract, green tea extract, turmeric extract, tart cherry, blueberry, broccoli, and kale. It is standardized to 60% polyphenols, 30% catechins, and 3% curcumin to ensure consistency, quality, and efficacy.
Our bodies produce nitric oxide which acts as a vasodilator, signaling the blood vessels to relax, therefore increasing blood flow. An increase in blood flow can aid athletes by delivering more oxygen, fuel, and other key nutrients to exercising muscles during workouts. Increased vasodilation and blood flow can also lead to a better muscle pump during a workout.
S7 has been shown to trigger our body’s own nitric oxide production system and significantly reduce oxidative stress in a peer reviewed published study. Participants that consumed S7 demonstrated increased bioavailable nitric oxide concentration, reduced reactive oxygen species (ROS), and improved cellular efficiency compared to baseline. ROS are created during both aerobic and anaerobic exercise. The increased antioxidant activity from S7 could reduce ROS created during exercise and decrease muscle fatigue and recovery time. All together S7 could be a dual function ingredient supporting increased blood flow and endurance.
CLINICALLY RESEARCHED S7 CLAIMS
- 230% acute boost in nitric oxide
- Supports the increase of circulating nitric oxide levels, known to promote healthy endothelial function and blood flow
- Protects against cellular damage
- Supports cellular efficiency and cellular function
- Reduces oxidative stress
THE CLINICAL RESEARCH
S7 is truly unique because it has been shown to deliver clinically supported, quantifiable nitric oxide increases and oxidative stress reductions directly in human participants. This is a major differentiator as the primary nitric oxide market tests nitric oxide potential via nitrate and nitrite levels. There are few nitric oxide boosters that cite clinically studied nitric oxide increases, and that research is either in vitro (outside of the body) or in rodents. In the acute study testing, the response of S7 in the body, the following results were found.
FutureCeuticals performed a double-blind, crossover, placebo-controlled peer-reviewed single-dose study. The purpose was to document the effects of S7 related to how this proprietary, plant-based ingredient influenced circulating bioavailable nitric oxide concentration and oxidative stress within 24-55 year-old healthy human participants. Following a low dose of 50mg, it was concluded that a statistically significant 230% increase in bioavailable nitric oxide was observed compared to baseline.
S7® is a registered trademark of VDF FutureCeuticals Inc.
These statements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.